Viridian Therapeutics, Inc.

This study tested the safety of an experimental drug called VRDN-001 for people with thyroid eye disease. The drug works by blocking a specific receptor to reduce inflammation and swelling around the eyes. The trial involved 231 participants and was designed to see how well peopl…

This Phase 3 clinical trial tested whether an investigational antibody drug called veligrotug could safely reduce eye bulging and other symptoms in people with chronic thyroid eye disease. The study involved 188 participants who received either the drug or a placebo through five …

This study gave continued access to an experimental drug called VRDN-001 to people with thyroid eye disease who did not improve enough in previous trials. The goal was to see if longer treatment could help reduce eye bulging and double vision, and to check the drug's safety. It i…